October 13, 2011
Denmark’s Novo Nordisk A/S has announced that the European Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of the long-acting basal insulin analogue Levemir (insulin detemir) for children aged two to five years with type I...read more